These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20499219)

  • 21. Preliminary assessment of carrageenan as excipient for extrusion/spheronisation.
    Bornhöft M; Thommes M; Kleinebudde P
    Eur J Pharm Biopharm; 2005 Jan; 59(1):127-31. PubMed ID: 15567309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preparation of Rhus chinensis total phenolic acid pellets by extrusion-spheronisation method].
    Lu XY; Xu W; Ye M; Chu KD; Xu W; Wang XY; Zheng HY
    Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(13):2785-2791. PubMed ID: 31359691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation of starch-based pellets by hot-melt extrusion.
    Bialleck S; Rein H
    Eur J Pharm Biopharm; 2011 Oct; 79(2):440-8. PubMed ID: 21570466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of starch-based pellets via extrusion/spheronisation.
    Dukić A; Mens R; Adriaensens P; Foreman P; Gelan J; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2007 Apr; 66(1):83-94. PubMed ID: 17045467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Approaches to developing fast release pellets via wet extrusion-spheronization.
    Xia Y; Shi CY; Fang JG; Wang WQ
    Pharm Dev Technol; 2018 Jun; 23(5):432-441. PubMed ID: 27882815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug release from MCC- and carrageenan-based pellets: experiment and theory.
    Kranz H; Jürgens K; Pinier M; Siepmann J
    Eur J Pharm Biopharm; 2009 Oct; 73(2):302-9. PubMed ID: 19465119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MUPS Tableting-Comparison between Crospovidone and Microcrystalline Cellulose Core Pellets.
    Thio DR; Heng PWS; Chan LW
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of liquid binder on the liquid mobility and preparation of spherical granules by the process of extrusion/spheronization.
    Boutell S; Newton JM; Bloor JR; Hayes G
    Int J Pharm; 2002 May; 238(1-2):61-76. PubMed ID: 11996811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Properties of drug-containing spherical pellets produced by a hot-melt extrusion and spheronization process.
    Young CR; Koleng JJ; McGinity JW
    J Microencapsul; 2003; 20(5):613-25. PubMed ID: 12909545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of water content and drug solubility on the formulation of pellets by extrusion and spheronisation.
    Lustig-Gustafsson C; Kaur Johal H; Podczeck F; Newton JM
    Eur J Pharm Sci; 1999 May; 8(2):147-52. PubMed ID: 10210738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Polymeric Excipients in the Stabilization of Olanzapine when Exposed to Aqueous Environments.
    Paisana M; Wahl M; Pinto J
    Molecules; 2015 Dec; 20(12):22364-82. PubMed ID: 26703534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of mass transfer during spheronisation.
    Koester M; Thommes M
    AAPS PharmSciTech; 2012 Jun; 13(2):493-7. PubMed ID: 22415640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation of ranitidine pellets by extrusion-spheronization with little or no microcrystalline cellulose.
    Basit AW; Newton JM; Lacey LF
    Pharm Dev Technol; 1999; 4(4):499-505. PubMed ID: 10578503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative extrusion-spheronization aids.
    Jain SP; Singh PP; Amin PD
    Drug Dev Ind Pharm; 2010 Nov; 36(11):1364-76. PubMed ID: 20521907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrusion-spheronisation of microcrystalline cellulose pastes using a non-aqueous liquid binder.
    Mascia S; Seiler C; Fitzpatrick S; Wilson DI
    Int J Pharm; 2010 Apr; 389(1-2):1-9. PubMed ID: 20123008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets.
    Morott JT; Pimparade M; Park JB; Worley CP; Majumdar S; Lian Z; Pinto E; Bi Y; Durig T; Repka MA
    J Pharm Sci; 2015 Jan; 104(1):124-34. PubMed ID: 25410968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of MCC II fraction and storage conditions on pellet properties.
    Krueger C; Thommes M; Kleinebudde P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1039-45. PubMed ID: 23872176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization.
    Goyanes A; Martínez-Pacheco R
    Drug Dev Ind Pharm; 2015 Mar; 41(3):362-8. PubMed ID: 24279425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-processed MCC-Eudragit® E excipients for extrusion-spheronization.
    Goyanes A; Souto C; Martínez-Pacheco R
    Eur J Pharm Biopharm; 2011 Nov; 79(3):658-63. PubMed ID: 21827853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chitosan-kaolin coprecipitate as disintegrant in microcrystalline cellulose-based pellets elaborated by extrusion-spheronization.
    Goyanes A; Souto C; Martínez-Pacheco R
    Pharm Dev Technol; 2013 Feb; 18(1):137-45. PubMed ID: 22309024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.